Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer

NAActive, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Locally Advanced HPV Positive Oropharynx Cancer

Interventions

RADIATION

PTV56

total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.

RADIATION

PTV50.4

total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT02945631 - Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer | Biotech Hunter | Biotech Hunter